NCT07392866 2026-02-09
A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 2/3 Not yet recruiting
Clinical Trials
9 trialsNCT07310173 2025-12-30
Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
Zhejiang Hisun Pharmaceutical Co. Ltd.
Phase 2 Recruiting
NCT04696055 2025-05-13
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Bayer
Phase 2 Completed
NCT05770882 2025-03-11
Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
Great Novel Therapeutics Biotech & Medicals Corporation
Phase 1/2 Terminated
NCT03890731 2024-04-02
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
Bayer
Phase 2 Completed
NCT03347292 2023-07-25
Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
Bayer
Phase 1 Completed
NCT03644511 2020-08-21
SORAGO-HCC
Bayer
Terminated
NCT01774344 2020-08-20
RESORCE
Bayer
Phase 3 Completed
NCT01003015 2015-04-03
Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma
Bayer
Phase 2 Completed